Clinical Trials Logo

MSI-H or dMMR Solid Tumors clinical trials

View clinical trials related to MSI-H or dMMR Solid Tumors.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03407976 Terminated - Clinical trials for Urothelial Carcinoma

Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies

APPEASE
Start date: June 19, 2018
Phase: Phase 1
Study type: Interventional

This is an open label nonrandomized Phase I/ IIA trial designed to assess the safety, tolerability, and efficacy of apatinib in combination with pembrolizumab. Phase I will assess the safety of combining increasing oral daily doses of apatinib with a fixed dose of IV pembrolizumab every three weeks and will determine the RP2D (Recommended Phase 2 Dose). Phase II will assess the efficacy of the RP2D of apatinib in combination with pembrolizumab and provide additional safety and tolerability data in three disease-specific cohorts